Exicure (FRA:2H0) Construction In Progress : €0.00 Mil (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Exicure Construction In Progress?

Exicure's annual construction in progress declined from Dec. 2021 (€0.03 Mil) to Dec. 2022 (€0.00 Mil) but then stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Exicure Construction In Progress Historical Data

The historical data trend for Exicure's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exicure Construction In Progress Chart

Exicure Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

0.32

0.10

0.03

Exicure Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Construction In Progress	Get a 7-Day Free Trial															-	-	-	-	-

Exicure Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Exicure Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (FRA:2H0) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

XCUR:USA 2H0A:Germany

Address

2430 N. Halsted Street, Suite 410, Chicago, IL, USA, 60614

Website

https://www.exicuretx.com

Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.

Exicure Headlines

No Headlines